Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientist in research and drug development. First founded in 2004 on the breakthrough innovations by Professor Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016, and Proseek multiplex panels now known as Olink Target and marketed by Olink Proteomics.
In 2016, Olink Bioscience became Navinci Diagnostics after the split from Olink Proteomics, which are now focused on using highly multiplexed protein biomarker analysis in circulation to improve precision medicine, and has recently been noted on Nasdaq NY.
Navinci has in close collaboration with Uppsala University continued to innovate the field of spatial biology with groundbreaking tools for studies of the tissue microenvironment.
In 2020, Navinci launched the next generation of proximity ligation assay techniques, our proprietary UnFold technology, to scientists worldwide in the NaveniFlex product line. We are now rapidly expanding our offering for in situ detection of protein interactions and post-translational modifications, not possible with standard techniques such as ImmunoFluorescence and ImmunoHistoChemistry.